Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avexa Limited
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Front panels for 34 SKUs for Haleon’s Nicorette 2- and 4-mg gum in approved to include a superimposed letter N; labeling approved for seven SKUs for Kenvue’s Zyrtec Allergy 5- and 10-mg tablets to include “new” for six months.
Futura Medical has extended its licensing agreement with Cooper Consumer Health for the rights to market its Eroxon topical, gel-based erectile dysfunction treatment throughout the European Economic Area, United Kingdom and Switzerland until 2029.
Plus deals involving AstraZeneca/Allorion, Concentra/Theseus, Janssen/MeiraGTx, Lilly/Fauna and more.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.